 |
 |
 |
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA
|
FOR IMMEDIATE RELEASE |
Media Inquiries: 301-827-6242 |
The Food and Drug Administration (FDA) has approved a stent for use in opening blocked arteries in the neck. The new stent is intended to prevent stroke by treating blockages in the carotid artery, the main blood vessel leading to the brain.
The device--the first of its kind--was approved for use in patients who have had symptoms of a stroke or whose carotid artery is at least 80 percent blocked, and who are not good candidates for the surgical alternative.
“Carotid stents offer doctors a new, less-invasive option for clearing blocked neck arteries,” said Dr. Lester M. Crawford, Acting FDA Commissioner. “This approval is another step forward in the prevention of stroke.”
Stents, which are small metal mesh tubes, are already approved for use in heart arteries. Currently, blockages in the carotid artery are treated with a surgical procedure called carotid endarterectomy in which surgeons cut into the neck artery to remove the blockage. Patients require general anesthesia for the procedure.
The new system, manufactured by Guidant Corporation, of Santa Clara, Calif., is inserted during angioplasty, a less invasive procedure in which the stent is threaded up to the neck artery via a catheter inserted in the groin. Patients usually require only local anesthesia.
The system can be used with a tiny filter that opens like an umbrella. The filter is used to catch and remove the debris that is stirred up during the stenting procedure before it floats to the brain where it can trigger a stroke.
FDA approved the system based on a review of clinical studies of safety and effectiveness conducted by Guidant.
The firm studied use of the carotid stent system in 581 patients at 45 medical centers who either had experienced a stroke or were in danger of having one due to severe blockages in the blood vessels in their neck.
The study showed that the new stent system successfully opened blockages in 92 percent of patients. When complications from use of the stent were compared to complications reported in the medical literature from patients undergoing surgery, the risk of combined complications of death, stroke and heart attack at 30 days or stroke in the area of the blockage at one year was about 10% compared to 15% for surgery. In addition, the study showed that the stent still allowed blood flow to the brain more than two years after the procedure.
FDA is requiring Guidant to conduct post-approval studies to confirm the stent’s performance in more patients and to assess its long-term safety and effectiveness in preventing strokes.
An estimated 200,000 Americans a year undergo carotid endarterectomy.
####